# The effect of locally applied platelet-rich fibrin on donor sites and recipient sites after splitthickness skin transplantation

Submission date 09/01/2006	<b>Recruitment status</b> No longer recruiting	<ul> <li>Prospectively registered</li> <li>Protocol</li> </ul>
<b>Registration date</b> 17/02/2006	<b>Overall study status</b> Completed	<ul> <li>[] Statistical analysis plan</li> <li>[X] Results</li> </ul>
Last Edited 24/07/2014	<b>Condition category</b> Circulatory System	Individual participant data

#### Plain English summary of protocol

Not provided at time of registration

### **Contact information**

**Type(s)** Scientific

**Contact name** Ms Patricia Danielsen

#### **Contact details**

Bispebjerg Hospital Afdeling K Bispebjerg Bakke 23 2400 Kobenhavn NV Denmark 2400 +45 (0)3531 3463 patriciadanielsen@yahoo.dk

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

(KF) 01286728

### Study information

Scientific Title

Acronym The Donor Study

**Study objectives** Platelet-rich fibrin shortens wound healing time and improves aesthetic outcome

**Ethics approval required** Old ethics approval format

Ethics approval(s) Yes, 19/09/2005, ref: (KF)01286728

**Study design** Randomised controlled trial

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Hospital

**Study type(s)** Quality of life

Participant information sheet

Health condition(s) or problem(s) studied Chronic leg ulcer

**Interventions** Split-thickness skin transplantation

Intervention Type Other

**Phase** Not Specified

**Primary outcome measure** Epithelialization on day five and nine post-operatively

#### Secondary outcome measures

- 1. Clinical appearance
- 2. Histological evaluation
- 3. Transepidermal Water Loss (TEWL)
- 4. Erythema
- 5. Microbiology
- 6. Incidence of infection
- 7. Unwanted side effects
- 8. Temperature difference between treated patients and control group patients

#### Overall study start date

01/01/2006

**Completion date** 

01/04/2007

# Eligibility

#### Key inclusion criteria

- 1. Patients undergoing surgery for chronic leg ulcer
- 2. Aged over 18 years
- 3. Written informed consent, the patient is expected to be able to complete the study
- 4. Donor site area from 2 x (3 cm x 5 cm) to 2 x (7.6 cm x 15 cm)

#### Participant type(s)

Patient

#### Age group

Adult

#### Lower age limit

18 Years

Sex Both

**Target number of participants** 20

#### Key exclusion criteria

- 1. Non-Danish speaking
- 2. Dementia
- 3. Pregnant or breastfeeding women
- 4. Patients treated with 10 mg of steroid or more daily
- 5. Patients that have received thrombocyte-inhibiting medicine less than four days before surgery
- 6. Patients not suited for general or spinal anaesthesia
- 7. Patients whose donor site has been used as a donor site before
- 8. Patients with skin diseases or pathological changes in the skin, including infection

Date of first enrolment 01/01/2006

Date of final enrolment 01/04/2007

### Locations

**Countries of recruitment** Denmark

**Study participating centre Bispebjerg Hospital** 2400 Kobenhavn NV Denmark 2400

### Sponsor information

**Organisation** Vivolution A/S (Denmark)

Sponsor details Blokken 45 3460 Birkeroed Denmark 3460 +45 (0)4581 1962 info@vivolution.dk

**Sponsor type** Industry

Website http://www.vivolution.com

ROR https://ror.org/010knjd35

### Funder(s)

**Funder type** Industry **Funder Name** Vivolution A/S (Denmark)

### **Results and Publications**

#### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2008		Yes	No
Results article	results	01/05/2013		Yes	No